US EditionPublished • loading... • Updated
Recent Research Analysts’ Ratings Updates for Spyre Therapeutics (SYRE)
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Recent Research Analysts’ Ratings Updates for Spyre Therapeutics (SYRE)
Spyre Therapeutics (NASDAQ: SYRE) has recently received a number of price target changes and ratings updates: 12/17/2025 – Spyre Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $64.00 price target on the stock. 12/15/2025 – Spyre Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
